NCT03340883 · MORE INFO

Limitations, agreements, and source contact

Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) · Source last updated 2021-04-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: Disclosure restriction - study results first published in a joint multi-center paper unless (a) no multi-center publication, or (b) ≥18 months has passed since completion of the study. Thereafter, Investigator may publish provided that Investigator: (i) provides a copy of the publication to Aduro ≥ 60 days in advance of submission for publication; (ii) deletes Aduro Confidential Information (other than the Study results) and (iii) submission may be delayed up to 90 days to permit IP filings.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: ADU-CL-16 was terminated early leading to a small number of Phase 1 subjects analyzed.

point Of Contact

Complete source fields

certain Agreement

other Details: Disclosure restriction - study results first published in a joint multi-center paper unless (a) no multi-center publication, or (b) ≥18 months has passed since completion of the study. Thereafter, Investigator may publish provided that Investigator: (i) provides a copy of the publication to Aduro ≥ 60 days in advance of submission for publication; (ii) deletes Aduro Confidential Information (other than the Study results) and (iii) submission may be delayed up to 90 days to permit IP filings.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: ADU-CL-16 was terminated early leading to a small number of Phase 1 subjects analyzed.

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice